Panelists discuss how current multiple sclerosis (MS) therapies show limited effectiveness against progression, but emerging ...

Multiple sclerosis (MS) is a chronic inflammatory disorder that is thought to impact about 2.3 million people around the ...

A trial using PET scans to test the anti-inflammatory drug PIPE-791 finished enrolling healthy volunteers and patients with ...

UC Riverside study may lead to new treatments for multiple sclerosis. Multiple sclerosis (MS) affects an estimated 2.3 ...

“These patent allowances in Canada and Israel complement the robust portfolio we've already secured for vafidemstat, further strengthening our global IP position and supporting its commercial ...

In multiple sclerosis, the ability of clinicians to provide a prognosis for a patient and the design and interpretation of clinical trials both rely heavily on prognostic factors identified from ...

The quest to mitigate disability progression in multiple sclerosis (MS) has long been hindered by our limited understanding of chronic or smouldering neuroinflammation and its drivers. Recent ...

AS a parent with a full-time job and a busy social life playing football and seeing friends, Adam Dawar always had somewhere to be. But when he went to bed feeling perfectly well one night and ...

Managed Healthcare Executive gives C-suite executives in health plans and provider organizations news and strategies for value-driven solutions.

In the HERCULES trial of non-relapsing secondary progressive MS, Fox reported a lower risk of confirmed disability progression sustained for at least 6 months with tolebrutinib compared with placebo.

Aleysha Ortiz graduated from Hartford Public High School with honors. That standing secured a seat in the freshman class at ...

A woman with a brain tumour, an NHS doctor and a woman with a chronic illness speak to the Cambrian News about the looming ...